XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Statement of Cash Flows [Abstract]    
Net income (loss) $ (22,682) $ 68,845
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Provision for (recovery of) bad debts (574) 493
Deferred tax benefit (6,531) (3,666)
Depreciation and amortization 19,454 20,587
Amortization of debt discount and issuance costs 13,653 2,160
Interest paid-in-kind 0 3,421
Equity-based compensation 11,706 3,264
Contingent consideration 1,071 16,008
Warranty provision 305 633
Provision for inventory obsolescence 654 2,517
Changes in operating assets and liabilities    
Accounts receivable (58,194) (22,340)
Inventories (55,321) 48,992
Income tax receivables 10,705 (15,890)
Prepaid expenses and other (5,770) 7,222
Accounts payable 1,948 (82,284)
Accounts payable - related party (1,622) (3,690)
Accrued expenses and other 1,683 4,644
Income tax payable (8,185) 6,584
Lease liabilities 337 0
Deferred revenue (68,474) (284,000)
Net cash used in operating activities (165,837) (226,500)
Cash flows used in investing activities    
Purchase of property, plant and equipment (2,252) (610)
Investment in equity security (11,975) 0
Net cash used in investing activities (14,227) (610)
Cash flows from financing activities    
Proceeds from revolving credit facility 102,000 32
Principal payments on term loan facility (132,150) (57,702)
Proceeds from Series A issuance 224,987 0
Proceeds from common stock issuance 120,645 0
Series A equity issuance costs 7,195 0
Common stock issuance costs (3,873) 0
Payments on revolving credit facility (102,000) 0
Payments on related party loans 0 (45,558)
Contingent consideration (7,810) 0
Deferred offering costs 0 (3,775)
Debt issuance costs 6,590 0
Net cash provided by (used in) financing activities 188,014 (107,003)
Net change in cash and cash equivalents 7,950 (334,113)
Cash and cash equivalents, beginning of period 108,441 361,257
Cash and cash equivalents, end of period $ 116,391 $ 27,144